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The major obstacle to cure infections with human immunodeﬁciency virus (HIV-1) is integrated proviral
genomes, which are not eliminated by antiretroviral therapies (ART). Treatment approaches with
latency-reversing agents (LRAs) aim at inducing provirus expression to tag latently-infected cells for
clearance through viral cytopathic effects or cytotoxic T cell (CTL) responses. However, the currently
tested LRAs reveal evident drawbacks as gene expression is globally induced and viral outgrowth is
insecure. Here, we present transcription activator-like effector (TALE) proteins as potent tools to activate
HIV-1 speciﬁcally. The large variety of circulating HIV-1 strains and, accordingly, integrated proviruses
was addressed by the programmable DNA-speciﬁcity of TALEs. Using customized engineered TALEs, a
substantial transcription activation and viral outgrowth was achieved with cells obtained from different
HIV-1 patients. Our data suggest that TALEs may be useful tools in future strategies aimed at removing
HIV-1 reservoirs.
& 2015 Elsevier Inc. All rights reserved.Introduction
ART has been a major accomplishment in HIV/AIDS treatment
as it enables a prolonged suppression of HIV replication resulting
in a decreased morbidity of HIV-1 infected patients (Van Lint et al.,
2013; Geeraert et al., 2008). However, even intensiﬁed ART treat-
ment cannot eradicate HIV-1, and viremia frequently rebounds
upon ART cessation (Finzi et al., 1997; Wong et al., 1997). New
strategies towards an HIV-1 cure aim at directly targeting the
integrated HIV-1 proviruses in cellular reservoirs, such as resting
memory CD4þ T cells, where viral gene expression is episodic or
silenced due to epigenetic, transcriptional or post-transcriptional
blocks (Choudhary and Margolis, 2011; Katlama et al., 2013; Xing
and Siliciano, 2013; Williams and Greene, 2007). A promising
approach to overcome HIV-1 latency while viral propagation is
inhibited by ART, is to induce viral gene expression to desig-
nate latently-infected cells for elimination by host immunealle.de (S.-E. Behrens).mechanisms or by viral cytopathic effects (‘shock and kill’ strat-
egy) (Geeraert et al., 2008). Along this line, mechanistically dis-
tinct LRAs were characterized that are capable to induce HIV-1
transcription in resting CD4þ T cells (Choudhary and Margolis,
2011; Katlama et al., 2013; Xing and Siliciano, 2013). One group of
LRAs is histone deacetylase inhibitors (HDACis), which stimulate
gene expression by histone acetylation-mediated chromatin
remodeling and transcriptional start site (TSS) release (Shirakawa
et al., 2013). However, HDACis, such as suberoylanilide hydroxamic
acid (SAHA, Vorinostat), bear drawbacks that relate to the global
up-regulation of cellular gene expression, which causes unpre-
dictable side effects and a considerable toxicity. Moreover, Vor-
inostat appears to fail to stimulate constant viral outgrowth, which
is an important prerequisite for subsequent CTL-mediated virus
elimination (Blazkova et al., 2012; Bullen et al., 2014; Cillo et al.,
2014). Other examples of LRAs are Disulﬁram and protein kinase C
(PKC) pathway agonists, which increase HIV-1 transcription by
activating cellular transcription factors that operate on the proviral
5’LTR (e.g. NF-κB, NFAT, AP-1, SP1). However, as with HDACis, this
stimulation is not restricted to HIV-1 infected cells (Van Lint et al.,
2013; Choudhary and Margolis, 2011; Katlama et al., 2013; Xing
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et al., 2014), and a successful treatment of different HIV-1 subtypes
is impeded by sequence variations in the transcription factor
binding sites (de Arellano et al., 2010). Clinical trials indeed
revealed no indications that LRAs may reduce latent HIV-1 reser-
voirs in infected individuals (Van Lint et al., 2013; Katlama et al.,
2013; Shirakawa et al., 2013; Cillo et al., 2014). This situation
highlights the need for speciﬁc and effective means to reverse
latency. These should (i) induce HIV-1 transcription in the absence
of global cell activation and toxicity and (ii) induce viral outgrowth
to label infected cells for elimination by the immune system.
Addressing these criteria, we followed a new strategy applying
HIV-1-speciﬁc transcription activator-like effectors (TALEs). TALEs
were originally characterized in plant-pathogenic bacteria that
translocate these proteins into host cells to reprogram gene
expression. TALEs contain a unique central DNA-binding domain
composed of nearly identical, tandem 34 aa repeats. Each repeat
binds to one DNA base pair, and a repeat-variable di-residue (RVD)
speciﬁes which base is recognized (Boch et al., 2009; Moscou and
Bogdanove, 2009). Accordingly, the DNA binding speciﬁcity of
TALEs can easily be engineered by choosing the number and order
of repeats. ‘Designer TALEs’ were shown to enable the speciﬁc
induction of human gene expression (Zhang et al., 2011; Geissler
et al., 2011; Renner et al., 2014).Results
13 TALEs (TALEs 1-13) were generated to target the HIV-1 pro-
moter region in the proviral 5’LTR (nucleotide position 172 to
16), which also contains the binding sites of natural transcription
factors. The TALEs consisted of 17.5 repeats and recognized over-
lapping stretches of 19 nucleotides in the 5’LTR, respectively (Fig. 1).
A non-HIV-targeting TALE (TALE 14) served as a negative control. To
support efﬁcient transcriptional activation in human cells, all TALEs
were generated with the transcription activation domain of herpes
simplex virus VP16, and all genes were codon-optimized. Codon-
optimization was essential to express the TALEs at high con-
centrations in human cells and to achieve a high efﬁcacy of tran-
scription activation (Supplementary Fig. 1) (Figs. 1 and 2).
To test TALEs 1–13 on the activation of an authentic HIV-1
provirus, we ﬁrst applied the human T cell line 8E5 that persis-
tently produces non-infectious HIV-1 particles at low titer (Folks
et al., 1986). Each 8E5 cell contains a single proviral DNA copy
integrated at a deﬁned genomic locus. Accordingly, all TALEs were
tested in an identical chromosomal background. Expression of the
TALE proteins in 8E5 cells was performed either by a murine ret-
roviral vector or by a HIV vector system (Fig. 2), of which both
strategies yielded analogous data. TALE 14 or the green ﬂuorescent
protein (GFP) was expressed as negative controls. MeasurementsFig. 1. HIV-1 ORFs and LTRs. Schematic representation of the HIV ORFs and LTRs. The se
factor binding sites and TATA box are underlined; the HS2 region is indicated. The targof the intracellular HIV-1 RNA levels by qRT-PCR and primers
recognizing the 50-terminal gag-coding region revealed a distinct
pattern of transcriptional induction in the 8E5 cells that expressed
TALEs 1-13 (see Fig. 1 and Fig. 3A).
While TALEs 10–13, which targeted the SP1 binding sites or
the TATA box, had no effect (comparable to the negative con-
trols), the HIV-1 transcription was signiﬁcantly stimulated in cells
that contained TALEs 1–9. TALEs 5 and 6, which targeted the
region between the LEF-1 and NF-κB binding sites induced the
intracellular level of HIV-1 RNA up to 65-fold. In comparison,
treatment of the cells with a non-cytotoxic concentration of
350 nM Vorinostat leads to an about 5-fold increase in intracel-
lular HIV-1 RNA synthesis, which is consistent with earlier
reports (Archin et al. (2012) and Fig. 3A). qRT-PCR measurements
with primers covering the genomic 3’-terminal nef-coding region
revealed a 10-fold increase in HIV-1 RNA levels by comparing
cells that expressed TALEs 5 and 14 (Fig. 1 and Fig. 3B). This
indicates that TALEs induce the transcription of full-length HIV-1
RNA, which is important for successful genome packaging. To
directly determine the amount of viral RNA that is released from
infected cells, we analyzed cell-free culture supernatants by qRT-
PCR detecting the nef-region. By comparing supernatants from
TALE 5-expressing and TALE 14-expressing cells, we detected an
approximately 30-fold increase in the number of released HIV-1
RNA molecules in the TALE 5-expressing cells (Fig. 3C). That is,
3105 8E5 control cells (expressing TALE 14 or GFP), produced
an average titer of 1.4105 HIV-1 RNA molecules per ml culture
medium (corresponding to 0.7105 virions per ml; one virion
contains two RNA molecules). The same number of TALE 5-
induced 8E5 cells produced about 4.2106 RNAs (2.1106 vir-
ions) per ml culture supernatant. Treatment with Vorinostat led
to an approximately 3-fold increase in the number of full-length
HIV-1 RNA molecules in the 8E5 supernatants (Fig. 3C).
To further evaluate the accessibility of the promoter region
between the LEF-1 and NF-κB, which was earlier termed as HS2
region (Van Lint et al., 1996), we tested two additional TALEs (15
and 16) that targeted the complementary DNA binding region of
TALE 5 and TALE 8, respectively. TALEs 15 and 16 induced HIV-1
transcription at similar efﬁcacy as TALEs 5 and 8 (Fig. 4) con-
ﬁrming that both strands of the proviral DNA are freely
approachable by TALEs. Moreover, these data demonstrated that
successful assembly of the transcription complex was deﬁned by
the TALE-binding position and not by the orientation or distance of
the VP16 activation domain to the HIV promoter’s TATA box.
In the following studies we investigated the most potent TALE
5 concerning its potential to enforce HIV-1 transcription and viral
outgrowth in infected primary cells. Peripheral blood mononuclear
cells (PBMCs) were isolated from two HIV-1 infected patients (P1,
P2), who achieved sustained control of viral replication during cART
(o50 RNA genome copies/ml). Considering the presence of SNPsquence of the -173 to -16 promoter region is highlighted on the left; transcription
et sequences of TALEs 1–13 are shown.
Fig. 2. Lentiviral vector constructs used for gene transfer of customized TALEs. (A). The vector contains self-inactivating (SIN) long terminal repeats (LTR: ΔU3, R, U5), a Rev
response element (RRE), central polypurine tract (cPPT), transgene cassette, post-regulatory element derived from woodchuck hepatitis virus (PRE), SV40 upstream poly-
adenylation enhancer element (USE), splice donor (SD), splice acceptor (SA), and packaging signal (Ψ). The open reading frame for enhanced GFP (egfp) is regulated by the
SFFV LTR promoter, the respective TALE-encoding sequences are regulated by the human EF1α promoter. The transcribed mRNAs are indicated by arrows. Note that the
lentiviral vector backbone does not contain any of the TALE 1–16 target sequences. (B) Efﬁciency of infection of 8E5 cells with lentiviral vector constructs. Left panel.
Differential interference contrast image of 8E5 cells. Right panel. GFP ﬂuorescence/differential interference contrast overlay image of 8E5 cells transduced with lentiviral
vector expressing TALE 5.
Fig. 3. TALEs induce HIV-1 transcription. (A, B) Intracellular levels of HIV-1 RNA in 8E5 expressing TALEs 1–14 analyzed by qRT-PCR with primers recognizing the (A) gag-
and (B) nef-coding region. The TALEs and GFP were expressed via retroviruses and the RNA levels analyzed 4 days post-infection. qRT-PCR data are presented as fold change
relative to the negative control (TALE 14; HIV-1 RNA level set to 1). TALE-mediated transcription induction was compared to that obtained by Vorinostat (VOR) or DMSO (-)
treatment. (C) Extracellular HIV-1 RNA levels in the supernatants of 8E5 that expressed TALE 5, TALE 14 or GFP or that were treated with VOR. qRT-PCR data with primers
recognizing the nef-coding region are presented as fold change relative to the controls (TALE 14 or (-); HIV-1 RNA level set to 1). Error bars indicate standard deviations of
three independent experiments, (**) Pr0.01, (***) Pr0.001.
Fig. 4. Both strands of the proviral DNA are accessible by TALEs. Left panel. Target sites of TALEs 3, 5, 8, 15 and 16 (promoter region -146 to -87); TALE orientation is indicated
by the VP16 activation domain. Right panel. HIV transcription induction of the respective TALEs in 8E5 relative to the control (TALE 14; HIV-1 RNA level set to 1). Intracellular
levels of HIV-1 RNA were quantiﬁed by qRT-PCR with primers recognizing the gag-coding region. Error bars indicate standard deviations of three independent experiments,
(***) Pr0.001.
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TALE 5 binding site within the HIV-1 5’LTR was ampliﬁed, cloned
and sequenced (Fig. 5). All analyzed clones obtained from P1 and P2
were found to contain a main SNP of a G to T exchange at position
-111 in comparison to the provirus strain (NL4-3) contained in 8E5.
For that reason, we generated a patient-adapted, ‘customized’ TALE(TALE P1/2) that optimally matched with the HIV-1 promoter region
of both patients (Fig. 5). Following lentiviral delivery and expression
of TALE P1/2 and TALE 14 in 1106 CD8þ T cell depleted PBMCs of
P1 and P2, respectively, the cell's vitality was conﬁrmed to be
unaffected, and the intracellular HIV-1 levels were analyzed by qRT-
PCR at day 6 post-infection.
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for the inoculation with lentiviruses that expressed either TALE P1/
P2 or the control TALE 14. Furthermore, by testing for activation
markers and HIV-1 release, the cells were controlled with respect
to HIV-1 activation, and it was demonstrated that the analyzed
amounts of PBMCs indeed contained integrated HIV-1 (Fig. 6). As
shown in Fig. 7A, by detecting the gag-coding region in cells thatFig. 5. HIV 5’LTR sequences (-136 to -95) in different clones derived from two HIV-
1 infected patients (P1 and P2).
Fig. 6. Tests of activated patient PBMCs for activation markers and HIV-1 release. CD8-de
2þPHA-PþPMA. At days 2, 4 and 6, the culture supernatants were analyzed for the pres
analysis (Left panels) or for virus load (Right panels).expressed TALE P1/2, a signiﬁcant increase of HIV-1 transcription
of 3 to 7-fold was observed in comparison to the TALE 14 negative
control. Interestingly, when we measured the levels of the HIV-1
protein p24 in the cell-free supernatant at days 6 and 10 by a
quantitative p24 antigen ELISA, these data indicated a substantial
viral outgrowth. That is, with TALE P1/2, the signal was elevated by
3- to 10-fold versus the control with TALE 14 (Fig. 7B and C). This
increase in the expression of viral protein by TALE P1/2 essentially
correlated with increased levels of full-length viral RNA molecules
in the PBMC supernatants during a time-course experiment of
several days: i.e., at day 10, P1 showed a ca. 100-fold increase, P2
showed a ca. 6-fold increase (Fig. 7D and E).
These data indicated that TALEs binding to speciﬁc sites of the
HIV-1 promoter are capable to speciﬁcally and efﬁciently induce
HIV-1 transcription and viral outgrowth in HIV-1 patient-derived
primary cells.Discussion
The success of future HIV-1 eradication strategies will critically
depend on the combination of various technical approaches. These
may include therapeutic vaccination strategies and gene therapies,
for example to inactivate the CCR5 receptor or to excise the inte-
grated proviral DNA (Shan et al., 2012; Perez et al., 2008; Sarkar
et al., 2007; Mitsuyasu et al., 2009; van Lunzen et al., 2007). The
currently most advanced approaches to eliminate latently-infected
cell reservoirs strive to enhance viral gene expression by smallpleted cells from the respective patients were stimulated with IL-2 alone or with IL-
ence of the indicated cell subsets by staining with monoclonal antibodies and FACS
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clearance by the host's immune system (Van Lint et al., 2013;
Choudhary and Margolis, 2011; Katlama et al., 2013; Xing and
Siliciano, 2013). Unfortunately, currently tested latency reversing
drugs frequently fail to induce HIV antigen production in latent
reservoirs (Blazkova et al., 2012; Bullen et al., 2014) and, further-
more, may also increase the susceptibility of uninfected cells to
HIV (Lucera et al., 2014). Moreover, it has been demonstrated that
various LRAs negatively interfere with CTL function (Jones et al.,
2014) and that a population of replication-competent proviruses
exists that cannot be induced with current LRAs (Ho et al., 2013).
Particularly the latter ﬁnding suggests that the size of the latent
reservoir is up to 60-fold greater than previously believed, thereby
signiﬁcantly raising the barrier to cure (Ho et al., 2013).
Here, we provide the proof of principle that ‘designer’ tran-
scription factors are capable to speciﬁcally and signiﬁcantly
increase HIV-1 gene expression in provirus-containing cells.
Although TALE delivery via lentiviral vectors required cellular
activation of target cells, careful control of our experiments
demonstrated signiﬁcant TALE-speciﬁc effects on transcriptional
activation of proviral DNAs. Thus, with the (non-stimulated) 8E5 T
cell line, the HIV-speciﬁc TALEs induced provirus transcription and
secretion of viral RNA into the supernatant, i.e., via the expression
of these TALEs, low HIV producing cells were modiﬁed into high
producing cells. Comparable data were obtained with the patient-
derived primary cells: also here, we demonstrated a TALE-
dependent signiﬁcant increase in viral transcription and out-
growth in addition to the PHA/PMA stimulation that was neces-
sary to achieve an efﬁcient transduction of the cells by the TALE-
expressing lentiviruses. Interestingly, with both types of cells, we
observed an efﬁcient TALE-driven transcription when the respec-
tive TALE targeted the HS2 region of the HIV-1 LTR enhancer
(Fig. 1; Fig. 3). While in other HIV provirus-containing cell types
HS2 was found to be hypersensitive to nucleases (Van Lint et al.,
1996), these results suggest that the HS2 HIV-1 promoter region
may be generally accessible for a TALE-mediated enforcement of
HIV gene expression. It is therefore expected that engineered
TALEs may also be highly useful for speciﬁc activation of compe-
tent reservoir proviruses that are otherwise not stimulated by
initial drug-based approaches (Ho et al., 2013).
In particular, TALEs may offer several key advantages in
potential anti-HIV future applications. (i) TALE activity supports
the highly increased production of viral RNA, proteins and
apparently virions, which is a major prerequisite for effective
clearance of latent reservoirs. (ii) TALEs induce HIV-1 gene
expression in a highly speciﬁc manner and, as demonstrated, the
TALE proteins may be customized to individual viruses. Hence, in
combination with next-generation sequencing to determine 5’LTR
variations and/or other proviral mutations, patient-adapted TALEs
may be designed. Along the same line, the problem that a large
majority of proviruses appears to be not induced by LRAs such as
HDACis (Blazkova et al., 2012; Bullen et al., 2014; Cillo et al., 2014)
may be addressed by speciﬁcally designed TALEs.
All applied TALEs could be successfully delivered and expressed
by lentiviral gene transfer. Thus, it is conceivable that more sui-
table vectors, which are currently tested in gene-therapeutic
approaches such as adenoviruses or adeno-associated viruses
(Kaufmann et al., 2013), may be applied to the TALE technology to
improve in vivo purging strategies. However, as with all types of
heterologous factors acting on HIV proviruses, the potential in vivo
usage of TALEs faces signiﬁcant technical issues such as the spe-
ciﬁc transfer to latently infected cells as well as immunological
issues that need to be solved.Conclusion
Our study suggests TALEs as an interesting tool to purge HIV
gene expression. In contrast to LRAs, TALEs enable a provirus-
speciﬁc, patient-adapted, induction of HIV transcription.Materials and methods
Construction of TALEs and expression plasmids
The DNA sequences encoding the applied TALEs based on the
hax3 gene of Xanthomonas campestris pv. Armoraciae. The coding-
unit of the Hax3 activation domain was replaced by the 68 aa VP16
domain. The genes of customized TALEs recognizing 19 nucleo-
tides of selected regions of the HIV-1 promoter region (Fig. 1) were
assembled with the ‘Golden TAL Technology’ (Geissler et al., 2011).
Brieﬂy, six single-repeat modules were ligated into assembly
vectors as a six-repeat array by cut-ligation using BpiI. To assemble
the complete TALE-coding sequence, three six-repeat arrays were
ligated with modules encoding a Flag-tag, the N- and C-terminus,
and the VP16 transcription activation domain, respectively, into an
expression vector pcDNA3 derivative using BsaI. The complete
nucleotide sequences of all applied TALEs are given as Supple-
mentary information. The amphotropic retroviral expression sys-
tem was purchased from Cell Biolabs. The lentiviral transfer
(pSH9), packaging (pMDLg/pRRE, pRSV-Rev) and envelope (pCMV-
VSV-G) plasmids were described previously (Hauber et al., 2013).
The TALE-encoding retroviral and lentiviral expression vectors
were generated by ligation of the respective TALE genes between
the EcoRI and XhoI restriction sites of pMXs-Neo (Cell Biolabs) and
pSH9, respectively. For codon-optimization of N- and C-termini
and the 34 aa repeats of hax3, we applied the tool GeneOptimizer
(Life Technologies) to improve the translation efﬁciency.
Cell culture, transfection and infection, treatment with Vorinostat
The retrovirus packaging cells Plat-A (Cell Biolabs) were grown
in Dulbecco's modiﬁed Eagle's Medium (Life Technologies) sup-
plemented with 10% FCS, 1% non-essential amino acids and 1%
penicillin/streptomycin. The CD4þT-lymphocyte cell line 8E5
(Folks et al., 1986) containing a single copy of a HIV-1 proviral
genome was cultured in RPMI-1640 medium (Life Technologies)
supplemented with 10% FCS, 1% L-glutamine and 1% penicillin/
streptomycin. For the expression of TALEs in the 8E5 cells, the
amphotropic retroviruses containing the TALE coding sequences
were generated with the Platinum Retrovirus Expression System
following the instructions of the manufacturer or with the lenti-
viral transfer and packaging system (see below). For expression via
retroviruses, Plat-A cells seeded in 6-wells were transfected at 50%
conﬂuence with 4 μg TALE-encoding retroviral expression plasmid
using Turbofect (ThermoScientiﬁc). The virus supernatant was
harvested 48 h post transfection and tested for the recommended
virus titers (Cell Biolabs). For the infection of the 8E5 cells, 20,000
cells were centrifuged at 400g and 20 °C for 5 min and the cell
pellet directly resuspended in 250 μl of the retrovirus-containing
supernatant (MOI of 10). Following the addition of 20 μg poly-
brene (Millipore), the infection was performed for 90 min at 400g
and 20 °C. Infected 8E5 cells were cultured for 4 days. Lentiviral
particles for infecting 8E5 cells or HIV-1 patient-derived PBMCs
were produced by transient transfection of 5106 Hek293T cells
with 6 μg of lentiviral transfer vector, 1.5 μg of pRSV-Rev, 1.5 μg of
pCMV-VSV-G and 3 μg of pMDLg/pRRE using TransIT-LT1 (Mirus
Bio LLC). At 72 h post transfection viral supernatants were col-
lected and passed through 0.2 μm pore size ﬁlters to ensure
removal of any viral aggregates. Viral particles were concentrated
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for further use. PBMCs from two HIV-1 patients were CD8þ T cell
depleted using the Human CD8 Positive Selection Kit (StemCell)
and pre-stimulated in RPMI-1640 medium (Lonza)þ10% FCS (PAN
Biotech) with 1 μg/ml PHA-P, 50 ng/ml PMA and 1 μg/ml poly-
brene (all from Sigma-Aldrich) for 24 h. The infection of PBMCs or
8E5 cells was performed with 1106 cells, respectively, using a
MOI of 10 for 90 min at 300g and 20 °C. Thereafter, the cells were
cultivated at 37 °C and 5% CO2 for 24 hours before the mediumwas
changed and the cells were further cultured. TALE expression was
measured by western blot and the transfection/transduction efﬁ-
ciencies were measured by co-expressed GFP (see Fig. 2). The
PBMCs were cultured in the presence of 10 U/ml human recom-
binant IL-2 (Biomol). The treatment of 8E5 cells with the histone
deacetylase inhibitor Vorinostat was performed with 350 nM
Vorinostat (Sigma-Aldrich; dissolved in DMSO) for 24 h and DMSO
as a control.
Quantitative RT-PCR and quantiﬁcation of viral load titers
For the quantiﬁcation of HIV-1 RNA contained in 8E5 cells,
cytoplasmic RNA was extracted. For cDNA synthesis, 1 μg of RNA
was heated for 5 min at 80 °C and reverse transcribed by Rever-
dAid H Minus Reverse Transcriptase (Fermentas) for 1 h at 42 °C
followed by heat inactivation for 10 min at 70 °C. HIV-1 RNA in
virus particles was isolated from 200 μl of 8E5 supernatant and
reverse transcribed as described above. Quantitative PCRs were
performed with LightCycler 480 SYBR Green I Master using a
LightCycler 480 (Roche). PCR conditions were: 95 °C 10 min, (95 °C
5 s; 60 °C 10 s; 72 °C 15 s)45 cycles. The qRT-PCR data were
analyzed by theΔΔCtmethod using GAPDH as an internal control.
For normalization of relative levels of HIV-1 RNAs in cell culture
supernatants, the supernatant was supplemented with 5 fmol of
Luc-polyA RNA prior to RNA extraction. The determined levels of
HIV-1 RNA were correlated to this control. HIV-1 RNA expression
in patient-derived CD8þ T cell-depleted PBMCs was measured by
ampliﬁcation of cDNA with Platinum Quantitative PCR SuperMix-
UDG/ROX Reference Dye (Life Technologies) for 40 cycles in a 7500
Fast Realtime PCR System (Applied Biosystems) at day 6 post-
infection. HIV-1 RNA levels were normalized to GAPDH. Cell-free
culture supernatant was assayed for viral load titer using the
ultrasensitive (o20 HIV-1 RNA copies/ml) Cobas AmpliPrep/Cobas
TaqMan HIV-1 Test version 2.0 (Roche). HIV-1 p24 levels in cell-
free culture supernatants of PBMCs were analyzed by HIV-1 p24
antigen ELISA (Innotest HIV p24 Antigen mAb; Innogenetics).
Patients
Patient 1 receives cART since 2001. At the time of blood draw
he had constantly suppressed viremia to below 20 RNA copies/ml
for more than ten years with few intermittent viral blips (o100
RNA copies/ml). His CD4 count was 278/μl (24%). Patient 2 was
diagnosed 1987. At the draw she received cART for more than ten
years. The viral load was constantly suppressed; the CD4 count
was 1167/μl (36%).
Characterization of activated patient PBMCs
Test for activation: The CD8-depleted patient PBMCs were
stained using CD4, CD11b, CD25, CD45 and CD69 monoclonal
antibodies and characterized for CD4þCD64þ , CD4þCD25þ ,
CD4þCD11bþ cell subsets by FACS analysis using a FACSCanto II
system with BD FACSDiva Software v5.0.3 and FlowJo software v7/
9 for PC (Treestar).
Test of viral load: 106 CD8-depleted patient cells were incubated in
1 ml RPMI1640-medium with 10% FCS, 2 mM L-Glutamin, 0.05 mg/mlPenicillin/Streptomycin together with recombinant human IL-2
[500 U] alone or rhIL-2þPHA-P [2 mg]þPMA [1 mg] in a 24-well
plate for 6 days. At day 2, 4 and 6 cell culture supernatant was ana-
lyzed for virus load using an ultrasensitive (o20 HIV-1 RNA copies/
ml) Cobas AmpliPrep/Cobas TaqMan HIV-1 Test version 2.0 assay.
Western blotting
Western blotting was performed using standard procedures.
The applied antibodies were purchased from Sigma-Aldrich (vin-
culin, V9131; FLAG, F7425), Invitrogen (GFP, A-6455), BD Phar-
mingen (CD45 FITC, 555482; CD69 APC, 555533), Beckman Coulter
(CD4 PE, A07751) and eBioscience (CD11b PE-Cy7, 25-0118-42;
CD25 APCFluor780, 47-0259). The secondary antibodies were from
GE Healthcare (anti-rabbit, NA934V; anti-mouse, NXA931).
Data evaluation/statistics
Data evaluation and statistics were done as described pre-
viously (Geissler et al., 2012).Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at 10.1016/j.virol.2015.09.018.Acknowledgments
This project was supported by the Deutsche Forschungsg
emeinschaft (BE 1885/9-1, BO 1496/6-1, CRC 648), the DZIF (Ger-
man Center for Infection Research), and the “Viral Latency” pro-
gram at the Heinrich Pette Institute.
RG, SEB, IH, JH and JB designed the experiments. RG, IH, JC,
HHS, AR, MB, IR, NF and HS performed the experiments. JvL sup-
plied patient material. RG, JH and SEB wrote the paper.References
Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M.,
et al., 2012. Administration of vorinostat disrupts HIV-1 latency in patients on
antiretroviral therapy. Nature 487, 482–485.
de Arellano, E.R., Alcami, J., Lopez, M., Soriano, V., Holguin, A., 2010. Drastic
decrease of transcription activity due to hypermutated long terminal repeat
(LTR) region in different HIV-1 subtypes and recombinants. Antivir. Res. 88,
152–159.
Blazkova, J., Chun, T.W., Belay, B.W., Murray, D., Justement, J.S., Funk, E.K., et al.,
2012. Effect of histone deacetylase inhibitors on HIV production in latently
infected, resting CD4(þ) T cells from infected individuals receiving effective
antiretroviral therapy. J. Infect. Dis. 206, 765–769.
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., et al., 2009.
Breaking the code of DNA binding speciﬁcity of TAL-type III effectors. Science
326, 1509–1512.
Bullen, C.K., Laird, G.M., Durand, C.M., Siliciano, J.D., Siliciano, R.F., 2014. New
ex vivo approaches distinguish effective and ineffective single agents for
reversing HIV-1 latency in vivo. Nat. Med. 20, 425–429.
Choudhary, S.K., Margolis, D.M., 2011. Curing HIV: Pharmacologic approaches to
target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51, 397–418.
Cillo, A.R., Sobolewski, M.D., Bosch, R.J., Fyne, E., Piatak Jr., M., Cofﬁn, J.M., Mellors, J.W.,
2014. Quantiﬁcation of HIV-1 latency reversal in resting CD4þ T cells from patients
on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 111, 7078–7083.
Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., et al.,
1997. Identiﬁcation of a reservoir for HIV-1 in patients on highly active anti-
retroviral therapy. Science 278, 1295–1300.
Folks, T.M., Powell, D., Lightfoote, M., Koenig, S., Fauci, A.S., Benn, S., et al., 1986.
Biological and biochemical characterization of a cloned Leu-3- cell surviving
infection with the acquired immune deﬁciency syndrome retrovirus. J. Exp.
Med. 164, 280–290.
Geeraert, L., Kraus, G., Pomerantz, R.J., 2008. Hide-and-seek: the challenge of viral
persistence in HIV-1 infection. Annu. Rev. Med. 59, 487–501.
R. Geissler et al. / Virology 486 (2015) 248–254254Geissler, R., Golbik, R.P., Behrens, S.E., 2012. The DEAD-box helicase DDX3 supports
the assembly of functional 80S ribosomes. Nucleic Acids Res. 40, 4998–5011.
Geissler, R., Scholze, H., Hahn, S., Streubel, J., Bonas, U., Behrens, S.E., Boch, J., 2011.
Transcriptional activators of human genes with programmable DNA-speciﬁcity.
PLoS One 6, e19509.
Hauber, I., Hofmann-Sieber, H., Chemnitz, J., Dubrau, D., Chusainow, J., Stucka, R.,
et al., 2013. Highly signiﬁcant antiviral activity of HIV-1 LTR-speciﬁc tre-
recombinase in humanized mice. PLoS Pathog. 9, e1003587.
Ho, Y.C., Shan, L., Hosmane, N.N., Wang, J., Laskey, S.B., et al., 2013. Replication-
competent noninduced proviruses in the latent reservoir increase barrier to
HIV-1 cure. Cell 155, 540–551.
Jones, R.B., O'Connor, R., Mueller, S., Foley, M., Szeto, G.L., et al., 2014. Histone
deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic
T-Lymphocytes. PLoS Pathog. 10, e1004287.
Katlama, C., Deeks, S.G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C.,
et al., 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1
reservoirs. Lancet 381, 2109–2117.
Kaufmann, K.B., Buning, H., Galy, A., Schambach, A., Grez, M., 2013. Gene therapy on
the move. EMBO Mol. Med. 5, 1642–1661.
Lucera, M.B., Tilton, C.A., Mao, H., et al., 2014. The histone deacetylase inhibitor
vorinostat (SAHA) increases the susceptibility of uninfected CD4þ T cells to HIV
by increasing the kinetics and efﬁciency of postentry viral events. J. Virol. 88,
10803–10812.
Mitsuyasu, R.T., Merigan, T.C., Carr, A., Zack, J.A., Winters, M.A., Workman, C., et al.,
2009. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34þ
cells. Nat. Med. 15, 285–292.
Moscou, M.J., Bogdanove, A.J., 2009. A simple cipher governs DNA recognition by
TAL effectors. Science 326, 1501–1508.
Perez, E.E., Wang, J., Miller, J.C., Jouvenot, Y., Kim, K.A., Liu, O., et al., 2008. Estab-
lishment of HIV-1 resistance in CD4þ T cells by genome editing using zinc-
ﬁnger nucleases. Nat. Biotechnol. 26, 808–816.Renner, I., Funk, N., Geissler, R., Friedrich, S., Penzel, A., Behrens, S.E., 2014. Antiviral
interferon-beta signaling induced by designed transcription activator-like
effectors (TALE). PLoS One 9, e114288.
Sarkar, I., Hauber, I., Hauber, J., Buchholz, F., 2007. HIV-1 proviral DNA excision
using an evolved recombinase. Science 316, 1912–1915.
Shan, L., Deng, K., Shroff, N.S., Durand, C.M., Rabi, S.A., Yang, H.C., et al., 2012. Sti-
mulation of HIV-1-speciﬁc cytolytic T lymphocytes facilitates elimination of
latent viral reservoir after virus reactivation. Immunity 36, 491–501.
Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V., Verdin, E., 2013. Reactivation of
latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21, 277–285.
Van Lint, C., Bouchat, S., Marcello, A., 2013. HIV-1 transcription and latency: an
update. Retrovirology 10, 67.
Van Lint, C., Emiliani, S., Ott, M., Verdin, E., 1996. Transcriptional activation and
chromatin remodeling of the HIV-1 promoter in response to histone acetyla-
tion. EMBO J. 15, 1112–1120.
van Lunzen, J., Glaunsinger, T., Stahmer, I., von Baehr, V., Baum, C., Schilz, A., et al.,
2007. Transfer of autologous gene-modiﬁed T cells in HIV-infected patients
with advanced immunodeﬁciency and drug-resistant virus. Mol. Ther. 15,
1024–1033.
Williams, S.A., Greene, W.C., 2007. Regulation of HIV-1 latency by T-cell activation.
Cytokine 39, 63–74.
Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A.,
Richman, D.D., 1997. Recovery of replication-competent HIV despite prolonged
suppression of plasma viremia. Science 278, 1291–1295.
Xing, S., Siliciano, R.F., 2013. Targeting HIV latency: pharmacologic strategies
toward eradication. Drug Discov. Today 18, 541–551.
Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M., Arlotta, P., 2011. Efﬁcient
construction of sequence-speciﬁc TAL effectors for modulating mammalian
transcription. Nat. Biotechnol. 29, 149–153.
